Most Clicked StoriesMore >


Amgen's drug for heart failure receives FDA approval

BIO SmartBrief | Apr 16, 2015

Amgen has obtained FDA approval for Corlanor, or ivabradine, as a treatment for chronic heart failure. The approval was supported by a study that demonstrated a lower risk of hospital readmission among patients treated with ivabradine, compared with placebo. Reuters (04/15)


Alkermes' assets purchased by Recro

BIO SmartBrief | Apr 15, 2015

AstraZeneca secures research partnership with PatientsLikeMe

BIO SmartBrief | Apr 15, 2015

Sanofi partners with Innate Pharma on antibody-drug conjugates

BIO SmartBrief | Apr 17, 2015

Mesoblast sells minority stake to Celgene for $44.4M

BIO SmartBrief | Apr 13, 2015

FDA grants breakthrough designation to peanut allergy patch

BIO SmartBrief | Apr 14, 2015

Eisai enters drug development deal with Genomics

BIO SmartBrief | Apr 14, 2015

Boehringer, Hydra enter renal disease drug development pact

BIO SmartBrief | Apr 16, 2015

Gene therapy developer receives $60M funding boost

BIO SmartBrief | Apr 14, 2015

IPO brings in $119M for Aduro Biotech

BIO SmartBrief | Apr 16, 2015


Find BIO SmartBrief Issues by Date:



BIO News More >


BIO International Convention -- Register Now

BIO SmartBrief | Apr 17, 2015

Faster & better connections with quality R&D vendors

BIO SmartBrief | Apr 16, 2015

Secure document sharing services optimized for life science organizations

BIO SmartBrief | Apr 16, 2015

Industrial biotechnology with a French twist!

BIO SmartBrief | Apr 15, 2015

Savings on environmental waste disposal services

BIO SmartBrief | Apr 14, 2015




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more